NeOnc Posts Q2 Loss, Sets August 12 for Phase 2a NEO100 Data
NTHI sits 19% above its 52-week low of $3.005 on elevated volume (2.5× avg).
Summary
NeOnc recorded a $14.2M Q2 loss and held only $2.0M in cash, but it confirmed that pivotal Phase 2a NEO100 data will be released on August 12, 2026 — a make-or-break moment for the company.
Key Events · Earnings and Guidance · NTHI
-
Q2 2026 Financial Results
Net loss of $14.2M ($0.58/share) on R&D spend of $2.6M; cash and equivalents stood at $2.0M as of June 30, 2026.
-
Phase 2a NEO100 Data Readout Confirmed
Topline results from the fully enrolled Phase 2a study in recurrent IDH1-mutant high-grade glioma will be presented on August 12, 2026.
-
Precarious Cash Position
With only $2.0M in cash, the company relies on an undrawn $10M line of credit and other capital sources; no shares were sold under the ATM or Mast Hill facility in Q2.
-
Board Appointment
Nasim Shomali joined the board effective July 1, 2026, bringing strategic and financial planning experience.
Analysis · NTHI · Life Sciences
A $14.2M quarterly net loss and a cash balance of just $2.0M highlight the financial strain at NeOnc. Yet the filing also locks in August 12 as the day topline results from the fully enrolled Phase 2a NEO100 study will be unveiled — a near-term binary event that could reshape the company's clinical trajectory. With liquidity this tight and a pivotal data readout days away, the stakes for investors are exceptionally high.
At the time of this filing, NTHI was trading at $3.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.8M. The 52-week trading range was $3.01 to $12.99. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.